We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Loses Exelon Patent Case Against Alvogen a Week After Winning Against Actavis
Novartis Loses Exelon Patent Case Against Alvogen a Week After Winning Against Actavis
A federal judge tossed out Novartis’ lawsuit against generic firm Alvogen’s challenge to its dementia treatment Exelon Patch, claiming the brand firm failed to show the generic product contained a patented antioxidant.